Early hypertension and prolonged mineralocorticoid therapy discontinuation in a child with salt-wasting 21-hydroxylase deficiency

J Endocrinol Invest. 2011 Feb;34(2):159-61. doi: 10.1007/BF03347048.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adrenal Hyperplasia, Congenital / drug therapy*
  • Adrenal Hyperplasia, Congenital / physiopathology
  • Anti-Inflammatory Agents / adverse effects
  • Anti-Inflammatory Agents / therapeutic use
  • Child, Preschool
  • Fludrocortisone / adverse effects
  • Fludrocortisone / analogs & derivatives
  • Fludrocortisone / therapeutic use
  • Humans
  • Hydrocortisone / adverse effects
  • Hydrocortisone / therapeutic use
  • Hypertension / etiology*
  • Infant, Newborn
  • Male
  • Mineralocorticoids / adverse effects*
  • Mineralocorticoids / therapeutic use*

Substances

  • Anti-Inflammatory Agents
  • Mineralocorticoids
  • Fludrocortisone
  • fludrocortisone acetate
  • Hydrocortisone

Supplementary concepts

  • Congenital adrenal hyperplasia due to 21 hydroxylase deficiency